Tango Therapeutics TNGX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$107.23M-5.5% | -$101.59M-1.1% | -$100.52M+30.9% | -$145.57M-10.1% | -$132.26M-1.5% | ||
| $2.12M-7.0% | $2.28M-5.8% | $2.42M-2.7% | $2.49M-0.3% | $2.5M-0.1% | ||
| $29.97M+13.4% | $26.43M-5.3% | $27.91M-1.9% | $28.47M-3.3% | $29.43M+1.9% | ||
| -$141.55M-1.9% | -$138.89M+4.8% | -$145.82M+1.6% | -$148.25M-9.5% | -$135.34M-2.9% | ||
| $995K-5.1% | $1.05M+10.3% | $950K+3.9% | $914K+49.8% | $610K-19.1% | ||
| -$61.83M-51.3% | -$40.87M-128% | $146.91M+11.3% | $132.01M+3.2% | $127.93M+48.5% | ||
| $302.34M+35.9% | $222.5M+5,336% | $4.09M+3.5% | $3.95M-15.6% | $4.68M-90.2% | ||
| $98.97M+132% | $42.75M+724% | $5.19M+142% | -$12.29M-350% | -$2.73M-219% | ||
| -$142.55M-1.9% | -$139.93M+4.7% | -$146.77M+1.6% | -$149.17M-9.7% | -$135.95M-2.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Tango Therapeutics's cash flow data come from?
- Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.